Open Nav

Sartar Therapeutics

  • Harri Sihto, Sartar Therapeutics

Seeking investments

  • Date:Wednesday, October 17
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Sartar Therapeutics develops a new targeted therapy for orphan cancer, gastrointestinal stromal tumor (GIST) based on discovery of novel oncogenes, phosphodiesterase 3 enzymes and repositioning and reformulation of an off-patent drug, anagrelide. The majority of GISTs become resistant for currently approved therapies. Anagrelide shows efficacy in those tumors and complements efficacy of Gleevec (Novartis) the current first-line therapy option for the patients. Sartar Develops a controlled-release anagrelide that will be administered once a week subcutaneously for the GIST patients. The candidate product will be developed up to phase I/II clinical trials and then out-licensed or sold to industry partners. Development will take up to 5 years and cost $5M. Sartar seeks seed/series A funding to take the candidate product up to clinical study phase.
  • Company Website:
  • Company HQ City:Helsinki
  • Company HQ Country:Finland
  • CEO/Top Company Official:Harri Sihto
  • Year Founded:2016
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development :controlled-released anagrelide
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:US patent granted.
  • Previous and Current Investors:founders, minor private investors
  • Size of Last Investment Round:$99,000
  • Total Amount Raised to Date, In All Rounds:$152,000
  • Address 1:Biomedicum Helsinki, room B418
  • Address 2:Haartmaninkatu 8
  • Address 3:00290 Helsinki
Harri Sihto
Sartar Therapeutics